

RECEIVED  
CENTRAL FAX CENTER

OCT 12 2005

## Clark &amp; Elbing LLP

101 Federal Street  
Boston, MA 02110Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046**Date:** October 12, 2005**To:** Examiner Audet  
U.S. Patent and Trademark Office  
Group Art Unit 1654**Facsimile No.:** 571-273-8300**From:** Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109**Re:** U.S. Patent Application Serial No. 09/551,336  
IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT  
FOR USE IN SUCH SYNTHESIS  
Holm et al.  
Filed: April 18, 2000  
Attorney Docket No.: 50412/016002  
Customer No. 21559**Pages:** 3, including cover page.**Message:** The following papers are enclosed:  
  
Revocation and New Power of Attorney (2 pages)

BEST AVAILABLE COPY

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

10-12-05  
15-10-03

17:54  
10:01

From-CLARK & ELBING LLP  
118 ELBING LANE, SUITE 100, ALEXANDRIA, VA 22313-1450

+6174287046  
118 ELBING LANE

T-380 P.002/003 F-575

RECEIVED  
CENTRAL FAX CENTER

OCT 12 2005

PATENT

ATTORNEY DOCKET NO. 50412/016002

Certificate of Facsimile Transmission: Date of Transmission: 10-12-05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 571-273-8300.

JANET D'ANNUNZIO-ELLIS

Printed Name of Person Faxing Transmission

Janet D'Annunzio-Ellis

Signature of Person Faxing Transmission

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Holm, et al.

Art Unit: 1654

Serial No.: 09/551,336

Examiner: Audet

Filed: April 18, 2000

Customer No.: 21559

Title: IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT FOR USE IN SUCH SYNTHESIS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Zealand Pharma A/S, a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of:

A chain of title from the inventors to the current assignee as shown below. Copies of the assignments or other documents in the chain of title are enclosed.

1. From Inventors Arne Holm and Bjarne Due Larsen to Zealand Pharmaceuticals A/S, as recorded in the Patent and Trademark Office at Reel 010760, Frame 0111, on April 18, 2000.

BEST AVAILABLE COPY

10-12-05  
12-10-05

17:54  
15:01

From-CLARK & ELBING LLP  
Fra-Zealand PHARMACEUTICALS A/S

+6174287046  
74999101010

T-380 P.003/003 F-575  
1-114 0-11741 1-749

2. From Zealand Pharmaceuticals A/S to Zealand Pharma A/S, by a  
Change of Name Certificate, as recorded in the Patent and  
Trademark Office at Reel 013152, Frame 0784, on August 5, 2002.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of  
attorney previously granted in the application and appoints the attorneys and/or agents of  
Clark & Elbing LLP, associated with customer number 21559, with full power of  
substitution and revocation, to prosecute the application and to transact all business in the  
United States Patent and Trademark Office connected therewith.

All correspondence regarding the application should be sent to the address  
associated with customer number 21559.

I hereby declare that all statements made herein of my own knowledge are true and  
that all statements made on information and belief are believed to be true; and further that  
these statements were made with the knowledge that willful false statements and the like  
so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18  
of the United States Code and that such willful false statements may jeopardize the  
validity of the application or any patents issued thereon.

Respectfully submitted,



Zealand Pharma A/S

Eva STEINNESS  
CEO

Date: 11/10/06

BEST AVAILABLE COPY